GKB Ophthalmics swings to profit after liquidating subsidiary
Consolidated net profit hit ₹3.03 crore as the company realized ₹11.70 crore from winding up GSV Ophthalmics. The firm remains in default.
— 2 earlier stories on GKB Ophthalmics Ltd. →What's new
- Consolidated net profit reached ₹3.03 crore, reversing a ₹7.08 crore loss.
- Operations revenue climbed 37% to ₹149.06 crore.
- The board passed on a dividend due to liquidity constraints and a Crisil D rating.
Why this matters
The liquidation of GSV Ophthalmics provided a cash injection equal to roughly 34% of the company's market capitalization. While this provides a temporary lifeline, the company remains in default. Investors should note that the standalone business still posted a loss, meaning the consolidated turnaround is heavily dependent on one-time divestment proceeds.
What we're watching
- Whether the company can exit its Crisil D default status.
- Future revenue growth on a standalone basis.
- Management's plan to address ongoing liquidity constraints.
The full read
GKB Ophthalmics posted a consolidated net profit of ₹3.03 crore for FY26, a sharp reversal from the ₹7.08 crore loss recorded the previous year. Revenue from operations rose 37% to ₹149.06 crore. The primary catalyst for this shift was the voluntary liquidation of its subsidiary, GSV Ophthalmics, which brought in ₹11.70 crore in proceeds. For a company with a market capitalization of just ₹34 crore, this cash recovery represents a massive 34% of its total value. Despite the consolidated profit, the company remains in a precarious position. It holds a Crisil D rating, indicating a debt default, and the standalone business continues to struggle with a net loss of ₹3.57 crore. The board has opted against a dividend to preserve cash. The turnaround is real, but it is heavily reliant on the one-time liquidation of a subsidiary rather than core operational health.
Questions answered
- How did GKB Ophthalmics move from a loss to a profit?
- The company reported a consolidated net profit of ₹3.03 crore, driven by a 37% revenue increase and the voluntary winding up of its subsidiary, GSV Ophthalmics.
- What was the financial impact of the GSV Ophthalmics liquidation?
- GKB realized total investment proceeds of ₹11.70 crore from the liquidation. This amount is significant for a company with a market capitalization of ₹34 crore.
- Is the company paying a dividend?
- No. The board decided against a dividend because the company faces liquidity constraints and maintains a Crisil D default rating.
- How did the standalone business perform?
- The standalone business remains loss-making, with a net loss of ₹3.57 crore for the year.
Story so far
All notes on GKB →- 27 May 2026 · 8:36 PM IST GKB Ophthalmics swings to profit after liquidating subsidiary
- today GKB Ophthalmics swings to profit as consolidated revenue jumps
- today GKB Ophthalmics is in default on ₹15.1 cr of bank debt